Published in Int Immunol on December 20, 2004
Neoadjuvant Anti-PD-1, Nivolumab in Resectable NSCLC (NA_00092076) | NCT02259621
Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma | NCT03918252
Nivolumab in Biochemically Recurrent dMMR Prostate Cancer | NCT04019964
Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci U S A (2007) 7.49
Checkpoint blockade in cancer immunotherapy. Adv Immunol (2006) 4.09
Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res (2011) 3.81
The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors. Neoplasia (2006) 3.54
Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer. Clin Cancer Res (2013) 3.48
Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma. J Clin Oncol (2013) 2.70
A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application. Nat Immunol (2013) 2.50
Prostate cancer as a model for tumour immunotherapy. Nat Rev Immunol (2010) 2.28
PD-1 as a potential target in cancer therapy. Cancer Med (2013) 1.98
Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment. J Immunother Cancer (2014) 1.92
At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy. J Leukoc Biol (2013) 1.90
The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma. Clin Ther (2015) 1.73
Overcoming T cell exhaustion in infection and cancer. Trends Immunol (2015) 1.72
Tumor infiltrating PD1-positive lymphocytes and the expression of PD-L1 predict poor prognosis of soft tissue sarcomas. PLoS One (2013) 1.44
Cancer immunotherapy: co-stimulatory agonists and co-inhibitory antagonists. Clin Exp Immunol (2009) 1.28
Prostate cancer immunotherapy. Clin Cancer Res (2011) 1.11
Genetic absence of PD-1 promotes accumulation of terminally differentiated exhausted CD8+ T cells. J Exp Med (2015) 1.06
Developing idiotype vaccines for lymphoma: from preclinical studies to phase III clinical trials. Br J Haematol (2008) 1.04
The programmed death-1 immune-suppressive pathway: barrier to antitumor immunity. J Immunol (2014) 1.01
Safety, correlative markers, and clinical results of adjuvant nivolumab in combination with vaccine in resected high-risk metastatic melanoma. Clin Cancer Res (2014) 1.01
OX40 Agonists and Combination Immunotherapy: Putting the Pedal to the Metal. Front Oncol (2015) 1.01
CD8+ T cells regulate bone tumor burden independent of osteoclast resorption. Cancer Res (2011) 1.00
Pembrolizumab. J Immunother Cancer (2015) 0.99
PD-1, PD-L1 (B7-H1) and Tumor-Site Immune Modulation Therapy: The Historical Perspective. J Hematol Oncol (2017) 0.99
DC-HIL/glycoprotein Nmb promotes growth of melanoma in mice by inhibiting the activation of tumor-reactive T cells. Cancer Res (2010) 0.99
Increased programmed death-1 expression on CD4+ T cells in cutaneous T-cell lymphoma: implications for immune suppression. Arch Dermatol (2010) 0.97
Targeting costimulatory molecules to improve antitumor immunity. J Biomed Biotechnol (2012) 0.96
The CD28-B7 Family in Anti-Tumor Immunity: Emerging Concepts in Cancer Immunotherapy. Immune Netw (2014) 0.96
Advances in the development of cancer immunotherapies. Trends Immunol (2012) 0.96
PD-1/PD-L1 blockade in cancer treatment: perspectives and issues. Int J Clin Oncol (2016) 0.95
Rational combinations of immunotherapeutics that target discrete pathways. J Immunother Cancer (2013) 0.95
Programmed death-1 blockade enhances the antitumor effects of peptide vaccine-induced peptide-specific cytotoxic T lymphocytes. Int J Oncol (2014) 0.93
Programmed death-1 and its ligand are novel immunotolerant molecules expressed on leukemic B cells in chronic lymphocytic leukemia. PLoS One (2012) 0.92
Immunotherapy for prostate cancer: biology and therapeutic approaches. J Clin Oncol (2011) 0.91
Inhibitory costimulation and anti-tumor immunity. Semin Cancer Biol (2007) 0.90
Combined immune checkpoint protein blockade and low dose whole body irradiation as immunotherapy for myeloma. J Immunother Cancer (2015) 0.88
Synergistic effects of soluble PD-1 and IL-21 on antitumor immunity against H22 murine hepatocellular carcinoma. Oncol Lett (2012) 0.87
Strategies and developments of immunotherapies in osteosarcoma. Oncol Lett (2015) 0.86
Nonoverlapping roles of PD-1 and FoxP3 in maintaining immune tolerance in a novel autoimmune pancreatitis mouse model. Proc Natl Acad Sci U S A (2016) 0.85
Mouse models in oncoimmunology. Nat Rev Cancer (2016) 0.85
Nivolumab in the treatment of malignant melanoma: review of the literature. Onco Targets Ther (2015) 0.84
Human Cancer Immunotherapy with PD-1/PD-L1 Blockade. Biomark Cancer (2015) 0.83
Immune checkpoints and immunotherapy for colorectal cancer. Gastroenterol Rep (Oxf) (2015) 0.83
From humble beginnings to success in the clinic: Chimeric antigen receptor-modified T-cells and implications for immunotherapy. Exp Biol Med (Maywood) (2015) 0.82
Cancer immunotherapies targeting the PD-1 signaling pathway. J Biomed Sci (2017) 0.82
Novel anti-melanoma immunotherapies: disarming tumor escape mechanisms. Clin Dev Immunol (2012) 0.82
Anti-programmed death receptor 1 immunotherapy in melanoma: rationale, evidence and clinical potential. Ther Adv Med Oncol (2015) 0.82
Burden of Nonsynonymous Mutations among TCGA Cancers and Candidate Immune Checkpoint Inhibitor Responses. Cancer Res (2016) 0.81
Clinical utility of nivolumab in the treatment of advanced melanoma. Ther Clin Risk Manag (2016) 0.81
From tumor immunosuppression to eradication: targeting homing and activity of immune effector cells to tumors. Clin Dev Immunol (2011) 0.80
PD-1 expression on dendritic cells suppresses CD8(+) T cell function and antitumor immunity. Oncoimmunology (2015) 0.80
PD-1 and its ligands are important immune checkpoints in cancer. Oncotarget (2016) 0.79
Targeting the MAPK and PI3K pathways in combination with PD1 blockade in melanoma. Oncoimmunology (2016) 0.78
Tumour-associated macrophages correlate with microvascular bed extension in colorectal cancer patients. J Cell Mol Med (2016) 0.77
Inhibitory RNA molecules in immunotherapy for cancer. Methods Mol Biol (2010) 0.77
Therapeutic vaccine for lymphoma. Yonsei Med J (2007) 0.77
Emerging strategies for cancer immunoprevention. Oncogene (2015) 0.77
Immunotherapy for prostate cancer enters its golden age. Clin Med Insights Oncol (2012) 0.77
Immunomodulation by MYB is associated with tumor relapse in patients with early stage colorectal cancer. Oncoimmunology (2016) 0.75
Chemoradiation Increases PD-L1 Expression in Certain Melanoma and Glioblastoma Cells. Front Immunol (2016) 0.75
PD-1 Suppresses Development of Humoral Responses That Protect against Tn-Bearing Tumors. Cancer Immunol Res (2016) 0.75
First-line treatment of metastatic melanoma: role of nivolumab. Immunotargets Ther (2017) 0.75
Immunoregulation in Fungal Diseases. Microorganisms (2016) 0.75
Cbl-b Deficiency Mediates Resistance to Programmed Death-Ligand 1/Programmed Death-1 Regulation. Front Immunol (2017) 0.75
Anti-SIRPα antibodies as a potential new tool for cancer immunotherapy. JCI Insight (2017) 0.75
Regulation of PD-L1 expression in a high-grade invasive human oral squamous cell carcinoma microenvironment. Int J Oncol (2016) 0.75
Metabolic shift induced by systemic activation of T cells in PD-1-deficient mice perturbs brain monoamines and emotional behavior. Nat Immunol (2017) 0.75
Cancer Clonal Theory, Immune Escape, and Their Evolving Roles in Cancer Multi-Agent Therapeutics. Curr Oncol Rep (2017) 0.75
Fractional Laser Releases Tumor-Associated Antigens in Poorly Immunogenic Tumor and Induces Systemic Immunity. Sci Rep (2017) 0.75
Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A (2002) 12.39
Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci U S A (2007) 7.49
PD-1 and PD-1 ligands: from discovery to clinical application. Int Immunol (2007) 6.24
Aberrant expansion of segmented filamentous bacteria in IgA-deficient gut. Proc Natl Acad Sci U S A (2004) 5.93
PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells. Cancer Res (2004) 5.59
Instruction of distinct CD4 T helper cell fates by different notch ligands on antigen-presenting cells. Cell (2004) 5.50
Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma. Cancer (2010) 5.05
Preferential generation of follicular B helper T cells from Foxp3+ T cells in gut Peyer's patches. Science (2009) 4.80
Inducible gene knockout of transcription factor recombination signal binding protein-J reveals its essential role in T versus B lineage decision. Int Immunol (2002) 4.66
The PD-1-PD-L pathway in immunological tolerance. Trends Immunol (2006) 4.52
Resting dendritic cells induce peripheral CD8+ T cell tolerance through PD-1 and CTLA-4. Nat Immunol (2005) 4.01
Haploinsufficient lethality and formation of arteriovenous malformations in Notch pathway mutants. Genes Dev (2004) 3.95
AID is required for c-myc/IgH chromosome translocations in vivo. Cell (2004) 3.89
PD-1:PD-L inhibitory pathway affects both CD4(+) and CD8(+) T cells and is overcome by IL-2. Eur J Immunol (2002) 3.78
Notch-RBP-J signaling is involved in cell fate determination of marginal zone B cells. Nat Immunol (2002) 3.75
Helicobacter pylori infection triggers aberrant expression of activation-induced cytidine deaminase in gastric epithelium. Nat Med (2007) 3.70
AID mutant analyses indicate requirement for class-switch-specific cofactors. Nat Immunol (2003) 3.69
Fibulin-5/DANCE is essential for elastogenesis in vivo. Nature (2002) 3.60
Critical roles of activation-induced cytidine deaminase in the homeostasis of gut flora. Science (2002) 3.58
Constitutive expression of AID leads to tumorigenesis. J Exp Med (2003) 3.16
AID enzyme-induced hypermutation in an actively transcribed gene in fibroblasts. Science (2002) 3.09
PD-1 inhibits antiviral immunity at the effector phase in the liver. J Exp Med (2003) 3.05
Loss of intestinal crypt progenitor cells owing to inactivation of both Notch1 and Notch2 is accompanied by derepression of CDK inhibitors p27Kip1 and p57Kip2. EMBO Rep (2008) 3.03
Regulation of alphabeta/gammadelta T cell lineage commitment and peripheral T cell responses by Notch/RBP-J signaling. Immunity (2004) 3.01
Uracil DNA glycosylase activity is dispensable for immunoglobulin class switch. Science (2004) 2.93
Differential expression of PD-L1 and PD-L2, ligands for an inhibitory receptor PD-1, in the cells of lymphohematopoietic tissues. Immunol Lett (2002) 2.80
AID is required for germinal center-derived lymphomagenesis. Nat Genet (2007) 2.79
Forebrain ependymal cells are Notch-dependent and generate neuroblasts and astrocytes after stroke. Nat Neurosci (2009) 2.74
Activation-induced cytidine deaminase shuttles between nucleus and cytoplasm like apolipoprotein B mRNA editing catalytic polypeptide 1. Proc Natl Acad Sci U S A (2004) 2.69
Molecular modeling and functional mapping of B7-H1 and B7-DC uncouple costimulatory function from PD-1 interaction. J Exp Med (2003) 2.66
Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice. Nat Med (2003) 2.65
Intestinal IgA synthesis: regulation of front-line body defences. Nat Rev Immunol (2003) 2.62
B1b lymphocytes confer T cell-independent long-lasting immunity. Immunity (2004) 2.60
A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application. Nat Immunol (2013) 2.50
Establishment of NOD-Pdcd1-/- mice as an efficient animal model of type I diabetes. Proc Natl Acad Sci U S A (2005) 2.49
The AID enzyme induces class switch recombination in fibroblasts. Nature (2002) 2.28
Activation-induced deaminase (AID)-directed hypermutation in the immunoglobulin Smu region: implication of AID involvement in a common step of class switch recombination and somatic hypermutation. J Exp Med (2002) 2.18
Separate domains of AID are required for somatic hypermutation and class-switch recombination. Nat Immunol (2004) 2.06
Regulation of marginal zone B cell development by MINT, a suppressor of Notch/RBP-J signaling pathway. Immunity (2003) 2.03
The PD-1/PD-L1 complex resembles the antigen-binding Fv domains of antibodies and T cell receptors. Proc Natl Acad Sci U S A (2008) 2.03
Regulation of lymphocyte development by Notch signaling. Nat Immunol (2007) 1.96
New regulatory co-receptors: inducible co-stimulator and PD-1. Curr Opin Immunol (2002) 1.92
PD-1 and LAG-3 inhibitory co-receptors act synergistically to prevent autoimmunity in mice. J Exp Med (2011) 1.80
The canonical Notch/RBP-J signaling pathway controls the balance of cell lineages in mammary epithelium during pregnancy. Dev Biol (2006) 1.80
Discovery of activation-induced cytidine deaminase, the engraver of antibody memory. Adv Immunol (2007) 1.80
Mice carrying a knock-in mutation of Aicda resulting in a defect in somatic hypermutation have impaired gut homeostasis and compromised mucosal defense. Nat Immunol (2011) 1.74
RBPjkappa-dependent Notch signaling regulates mesenchymal progenitor cell proliferation and differentiation during skeletal development. Development (2010) 1.72
Initiation of NALT organogenesis is independent of the IL-7R, LTbetaR, and NIK signaling pathways but requires the Id2 gene and CD3(-)CD4(+)CD45(+) cells. Immunity (2002) 1.70
Role of AID in tumorigenesis. Adv Immunol (2007) 1.69
Learning and memory deficits in Notch mutant mice. Curr Biol (2003) 1.68
IFN-α directly promotes programmed cell death-1 transcription and limits the duration of T cell-mediated immunity. J Immunol (2011) 1.64
Apex2 is required for efficient somatic hypermutation but not for class switch recombination of immunoglobulin genes. Int Immunol (2009) 1.62
Inhibition of Notch/RBP-J signaling induces hair cell formation in neonate mouse cochleas. J Mol Med (Berl) (2005) 1.61
Oncogenic activation of the Notch1 gene by deletion of its promoter in Ikaros-deficient T-ALL. Blood (2010) 1.60
Cutting Edge: Ectopic expression of CD40 ligand on B cells induces lupus-like autoimmune disease. J Immunol (2002) 1.55
The interleukin-4 enhancer CNS-2 is regulated by Notch signals and controls initial expression in NKT cells and memory-type CD4 T cells. Immunity (2006) 1.53
Multiple roles of Notch signaling in cochlear development. Dev Biol (2007) 1.48
Notch/RBP-J signaling regulates epidermis/hair fate determination of hair follicular stem cells. Curr Biol (2003) 1.46
Recombination signal sequence-binding protein Jkappa alters mesodermal cell fate decisions by suppressing cardiomyogenesis. Proc Natl Acad Sci U S A (2003) 1.45
De novo protein synthesis is required for the activation-induced cytidine deaminase function in class-switch recombination. Proc Natl Acad Sci U S A (2003) 1.43
B cell-specific and stimulation-responsive enhancers derepress Aicda by overcoming the effects of silencers. Nat Immunol (2009) 1.41
Activation-induced cytidine deaminase links between inflammation and the development of colitis-associated colorectal cancers. Gastroenterology (2008) 1.37
AID-deficient Bcl-xL transgenic mice develop delayed atypical plasma cell tumors with unusual Ig/Myc chromosomal rearrangements. J Exp Med (2007) 1.37
Complex interplay between β-catenin signalling and Notch effectors in intestinal tumorigenesis. Gut (2011) 1.33
Negative regulation of activation-induced cytidine deaminase in B cells. Proc Natl Acad Sci U S A (2006) 1.30
Histone3 lysine4 trimethylation regulated by the facilitates chromatin transcription complex is critical for DNA cleavage in class switch recombination. Proc Natl Acad Sci U S A (2010) 1.30
Notch/Rbp-j signaling prevents premature endocrine and ductal cell differentiation in the pancreas. Cell Metab (2006) 1.28
Elimination of local macrophages in intestine prevents chronic colitis in interleukin-10-deficient mice. Dig Dis Sci (2003) 1.28
Cartilage-specific RBPjκ-dependent and -independent Notch signals regulate cartilage and bone development. Development (2012) 1.28
Absence of programmed death receptor 1 alters thymic development and enhances generation of CD4/CD8 double-negative TCR-transgenic T cells. J Immunol (2003) 1.26
Nonimmunoglobulin target loci of activation-induced cytidine deaminase (AID) share unique features with immunoglobulin genes. Proc Natl Acad Sci U S A (2012) 1.26
Type two hyper-IgM syndrome caused by mutation in activation-induced cytidine deaminase. J Med Dent Sci (2003) 1.25
TRIM28 prevents autoinflammatory T cell development in vivo. Nat Immunol (2012) 1.19
Peripheral deletional tolerance of alloreactive CD8 but not CD4 T cells is dependent on the PD-1/PD-L1 pathway. Blood (2008) 1.19
The C-terminal region of activation-induced cytidine deaminase is responsible for a recombination function other than DNA cleavage in class switch recombination. Proc Natl Acad Sci U S A (2009) 1.18
Activation-induced cytidine deaminase (AID) promotes B cell lymphomagenesis in Emu-cmyc transgenic mice. Proc Natl Acad Sci U S A (2007) 1.15
Adenovirus-mediated gene delivery and in vitro microinsemination produce offspring from infertile male mice. Proc Natl Acad Sci U S A (2002) 1.15
Evolution of class switch recombination function in fish activation-induced cytidine deaminase, AID. Int Immunol (2005) 1.15
Requirement of non-canonical activity of uracil DNA glycosylase for class switch recombination. J Biol Chem (2006) 1.15
Unmutated immunoglobulin M can protect mice from death by influenza virus infection. J Exp Med (2003) 1.15
Two opposing roles of RBP-J in Notch signaling. Curr Top Dev Biol (2010) 1.15
PD-1-mediated suppression of IL-2 production induces CD8+ T cell anergy in vivo. J Immunol (2009) 1.14
DNA double-strand breaks: prior to but not sufficient in targeting hypermutation. J Exp Med (2002) 1.13
Msx2-interacting nuclear target protein (Mint) deficiency reveals negative regulation of early thymocyte differentiation by Notch/RBP-J signaling. Proc Natl Acad Sci U S A (2007) 1.11
Rejuvenating exhausted T cells during chronic viral infection. Cell (2006) 1.11
AID-induced decrease in topoisomerase 1 induces DNA structural alteration and DNA cleavage for class switch recombination. Proc Natl Acad Sci U S A (2009) 1.10
CD4+ PD-1+ T cells accumulate as unique anergic cells in rheumatoid arthritis synovial fluid. J Rheumatol (2003) 1.09
DNA cleavage in immunoglobulin somatic hypermutation depends on de novo protein synthesis but not on uracil DNA glycosylase. Proc Natl Acad Sci U S A (2005) 1.05
Allogeneic offspring produced by male germ line stem cell transplantation into infertile mouse testis. Biol Reprod (2003) 1.05
Regulation of IgA synthesis at mucosal surfaces. Curr Opin Immunol (2004) 1.04
A target selection of somatic hypermutations is regulated similarly between T and B cells upon activation-induced cytidine deaminase expression. Proc Natl Acad Sci U S A (2005) 1.04
An evolutionary view of the mechanism for immune and genome diversity. J Immunol (2012) 1.04
De novo protein synthesis is required for activation-induced cytidine deaminase-dependent DNA cleavage in immunoglobulin class switch recombination. Proc Natl Acad Sci U S A (2004) 1.04
Organ-specific profiles of genetic changes in cancers caused by activation-induced cytidine deaminase expression. Int J Cancer (2008) 1.04
Microanatomical localization of PD-1 in human tonsils. Immunol Lett (2002) 1.02
RNA-editing cytidine deaminase Apobec-1 is unable to induce somatic hypermutation in mammalian cells. Proc Natl Acad Sci U S A (2003) 1.02